Phase 1 trial of gemtuzumab ozogamicin in combination with enocitabine and daunorubicin for elderly patients with relapsed or refractory acute myeloid leukemia: Japan Adult Leukemia Study Group (JALSG)-GML208 study

International Journal of Hematology

Volumn 96, Issue 4, 2012, Pages 485-491

  Ito, Yoshikazu ^a   Wakita, Atsushi ^b   Takada, Satoru ^c   Mihara, Masahiro ^d   Gotoh, Moritaka ^a   Ohyashiki, Kazuma ^a   Ohtake, Shigeki ^e   Miyawaki, Shuichi ^f   Ohnishi, Kazunori ^g   Naoe, Tomoki ^h  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b Nagoya City University West Medical Center   (Japan)

^c SAISEIKAI MAEBASHI HOSPITAL   (Japan)

^d Fujioka General Hospital   (Japan)

^e KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^f Hematology Division   (Japan)

^g HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Acute myeloid leukemia; Chemotherapy; Elderly; Gemtuzumab ozogamicin

Indexed keywords

ANTIHISTAMINIC AGENT; CORTICOSTEROID; CYTARABINE; DAUNORUBICIN; ENOCITABINE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER RECURRENCE; CANCER REGRESSION; CASE REPORT; COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPOALBUMINEMIA; HYPOKALEMIA; HYPONATREMIA; INFUSION RELATED REACTION; JAPAN; KARYOTYPE; MALE; MAXIMUM TOLERATED DOSE; NEUTROPENIA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PRURITUS; RECURRENCE FREE SURVIVAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME;

AGED; AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DAUNORUBICIN; FEMALE; HUMANS; JAPAN; LEUKEMIA, MYELOID, ACUTE; MALE; NEOPLASM STAGING; RECURRENCE; TREATMENT OUTCOME;

EID: 84868123930     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-012-1165-z     Document Type: Article

References (26)

1. Burnett A, Wetzler M, Lowenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol. 2011;29:487-94.
2. Dombret H, Raffoux E, Gardin C. Acute myeloid leukemia in the elderly. Semin Oncol. 2008;35:430-8.
3. Buchner T, Berdel WE, Wormann B, Schoch C, Haferlach T, Schnittger S, et al. Treatment of older patients with AML. Crit Rev Oncol Hematol. 2005;56:247-59. (Pubitemid 41568580)
4. Sievers EL, Larson RA, Stadtmauer EA, Estey E, Lowenberg B, Dombret H, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001;19:3244-54. (Pubitemid 32591442)
5. Larson RA. Current use and future development of gemtuzumab ozogamicin. Semin Hematol. 2001;38(suppl 6):24-31. (Pubitemid 32717672)
6. Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res. 2001;7:1490-6. (Pubitemid 32708610)
7. Larson RA, Boogaerts M, Estey E, Karanes C, Stadtmauer EA, Sievers EL, et al. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia. 2002;16:1627-36.
8. Kobayashi Y, Tobinai K, Takeshita A, Naito K, Asai O, Dobashi N, et al. Phase I/II study of humanized anti-CD33 antibody conjugated with calicheamicin, gemtuzumab ozogamicin, in relapsed or refractory acute myeloid leukemia: final results of Japanese multicenter cooperative study. Int J Hematol. 2009;89: 460-9.
9. Burnett AK, Hills RK, Milligan D, Kjeldsen L, Kell J, Russell NH, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol. 2011;29:369-77.
10. Castaigne S, Pautas C, Terré C, Raffoux E, Bordessoule D, Bastie JN, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012;379: 1508-16.
11. Petersdorf S, Kopecky K, Stuart RK, Larson RA, Nevill TJ, Stenke L, et al. Preliminary results of Southwest Oncology Group Study S0106: an international intergroup phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to post-consolidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia. Blood. 2009;114:326-7a (Abstract 790).
12. Mori M, Ohta M, Miyata A, Higashihara M, Oshimi K, Kimura H, et al. Treatment of acute myeloid leukemia patients aged more than 75 years: results of the E-AML-01 trial of the Japanese Elderly Leukemia and Lymphoma Study Group (JELLSG). Leuk Lymphoma. 2006;47:2062-9. (Pubitemid 44650081)
13. Wakita A, Ohtake S, Takada S, Yagasaki F, Komatsu H, Miyazaki Y, et al. Randomized comparison of fixed-schedule versus response-oriented individualized induction therapy and use of ubenimex during and after consolidation therapy for elderly patients with acute myeloid leukemia: the JALSG GML200 Study. Int J Hematol. 2012;96:84-93.
14. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood. 1998;92:2322-33. (Pubitemid 28452973)
15. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003;21:4642-9. (Pubitemid 46594039)
16. Tanaka M, Kano Y, Akutsu M, Tsunoda S, Izumi T, Yazawa Y, et al. The cytotoxic effects of gemtuzumab ozogamicin (Mylotarg) in combination with conventional antileukemic agents by isobologram analysis in vitro. Anticancer Res. 2009;29:4589-96.
17. Usui N, Takeshita A, Nakaseko C, Dobashi N, Fujita H, Kiyoi H, et al. Phase I trial of gemtuzumab ozogamicin in intensive combination chemotherapy for relapsed or refractory adult acute myeloid leukemia (AML): Japan Adult Leukemia Study Group (JALSG)-AML206 study. Cancer Sci. 2011;102:1358-65.
18. De Angelo DJ, Stone RM, Durrant S, Liu DL, Baccarani M, Schiffer CA, et al. Gemtuzumab ozogamicin (Mylotarg (R)) in combination with induction chemotherapy for the treatment of patients with de novo acute myeloid leukemia: Two age-specific phase 2 trials. Blood. 2003;102:100a (Abstract 341).
19. Piccaluga PP, Martinelli G, Rondoni M, Malagola M, Gaitani S, Visani G, et al. First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients. Leuk Res. 2004;28:987-90. (Pubitemid 38953654)
20. Stone RM, Moser B, Sanford B, Schulman P, Kolitz JE, Allen S, et al. High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: cancer and Leukemia Group B study 19902. Leuk Res. 2011;35:329-33.
21. Fianchi L, Pagano L, Leoni F, Storti S, Voso MT, Valentini CG, et al. Gemtuzumab ozogamicin, cytosine arabinoside, G-CSF combination (G-AraMy) in the treatment of elderly patients with poor-prognosis acute myeloid leukemia. Ann Oncol. 2008;19: 128-34.
22. Clavio M, Vignolo L, Albarello A, Varaldo R, Pierri I, Catania G, et al. Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukaemia: results of a prospective, pilot, multi-centre trial and comparison with a historical cohort of patients. Br J Haematol. 2007;138:186-95. (Pubitemid 46976329)
23. Pirrotta MT, Bocchia M, Bucalossi A, Defina M, Forconi F, Gozzetti A, et al. Pilot study of gemtuzumab ozogamicin (GO), fludarabine, cytarabine and idarubicin combined regimen (GOFLAI) as first-line induction therapy plus GO alone as consolidation therapy for elderly acute myeloid leukemia patients. Acta Haematol. 2007;118:7-9. (Pubitemid 47014334)
24. Eom KS, Kim HJ, Min WS, Lee S, Min CK, Cho BS, et al. Gemtuzumab ozogamicin in combination with attenuated doses of standard induction chemotherapy can successfully induce complete remission without increasing toxicity in patients with acute myeloid leukemia aged 55 or older. Eur J Haematol. 2007;79:398-404. (Pubitemid 47556490)
25. Brunnberg U, Mohr M, Noppeney R, Dürk HA, Sauerland MC, Müller-Tidow C, et al. Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients. Ann Oncol. 2012;23:990-6.
26. Ohtake S, Miyawaki S, Fujita H, Kiyoi H, Shinagawa K, Usui N, et al. Randomized study of induction therapy comparing standard- dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study. Blood. 2011;117:2358-65.